Friday 6 November 2026
Export GSK’s income statement to Excel — free account
GSK PLC Sponsored ADR
GSK Healthcare Drug Manufacturers General
GSK PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $43.1 billion, up 7.44% from fiscal 2024.
- Revenue
- +3.75%
- EPS
- −14.7%
- Free cash flow
- +62.4%
- Total debt
- +33.2%
Quarter to September 2026, against a year earlier
50.34
0.07
−0.14%
Follow GSK
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
9 | 8 | 8 | 6 |
| 39.92% | 38.52% | 30.74% | 25.48% | ||
| 9.63% | 9.72% | 8.01% | 6.53% | ||
ROIC |
16.44% | 15.14% | 12.58% | 9.61% | |
Return on Tangible Assets |
105.05% | 124.42% | 89.82% | 65.86% | |
Average Days of Receivables |
86.69 | 88.94 | 88.86 | 93.11 | |
Free Cash Flow per Share |
3.19 | 3.25 | 3.81 | 4.41 | |
Free Cash Flow |
6,455.04 | 6,540.67 | 7,647.98 | 8,830.02 | |
Capital Expenditures |
(3,753.02) | (3,762.76) | (3,372.99) | (2,944.60) | |
| Other line items | |||||
Cash ROIC |
13.16% | 12.13% | 14.76% | 14.55% | |
Accounts Receivable Turnover |
4.40 | 4.36 | 4.22 | 3.97 | |
Accounts Payable Turnover |
0.60 | 0.62 | 0.62 | 0.58 | |
Inventory Turnover |
1.58 | 1.51 | 1.47 | 1.47 | |
Average Days of Payables |
622.61 | 588.64 | 579.33 | 624.01 | |
Days of Inventory on Hand |
239.80 | 252.83 | 253.75 | 251.47 | |
Tax Rate |
(0.15) | (0.15) | (0.11) | (0.10) | |
Research and Development Expense of Revenue |
23.04% | 23.61% | 27.66% | 28.26% | |
Selling, General and Administrative Expense of Revenue |
27.82% | 27.87% | 27.70% | 27.85% | |
Share Based Compensation of Revenue |
4.05% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
11.32 | 11.38 | 9.22 | 7.96 | |
Operating CF/Net income |
1.35 | 1.32 | 1.70 | 2.01 | |
Depreciation/Fixed assets |
0.25 | 0.21 | 0.33 | 0.33 | |
Capex/Depreciation |
(1.23) | (1.43) | (0.82) | (0.71) | |
Revenue per Share |
21.27 | 21.82 | 22.18 | 22.42 | |
Operating CF per Share |
5.04 | 5.12 | 5.49 | 5.87 | |
Capex per Share |
(1.85) | (1.87) | (1.68) | (1.47) | |
Capex to Sales |
0.09 | 0.09 | 0.08 | 0.07 |
Columns are period end dates · fundamentals updated 2 Nov 2026